Towards Healthcare

In Vitro Diagnostics Companies Market Position Advancements, Value Creation, Cross-border Expansion, Patent Expansions, Financial Performance Evaluation

Date : 13 January 2025

In Vitro Diagnostics Key Players and their Developments

The global in vitro diagnostics market was estimated at US$ 77.95 billion in 2023 and is projected to grow to US$ 123.45 billion by 2034, rising at a compound annual growth rate (CAGR) of 4.45% from 2024 to 2034.

In-Vitro Diagnostics Market Companies

Top Companies in the In Vitro Diagnostics Market

  • BD
  • F. Hoffmann-La Roche Ltd.
  • Qiagen 
  • Siemens Healthineers AG 
  • Agilent Technologies, Inc. 
  • Bio-Rad Laboratories, Inc. 
  • QuidelOrtho Corporation 
  • Charles River Laboratories
  • Abbott 
  • Danaher Corporation 
  • bioMérieux SA
  • Quest Diagnostics Incorporated 
  • Sysmex Corporation

Innovation by Roche in the In Vitro Diagnostics Market

Company Name F. Hoffmann-La Roche Ltd. 
Headquarters  Basel, Switzerland, Europe 
Recent Development  In September 2024, with the addition of over 20 cutting-edge artificial intelligence (AI) algorithms from eight new partners, Roche announced the expansion of its digital pathology open environment. Using state-of-the-art AI technology, these strategic partnerships seek to assist scientists and pathologists in the study and detection of cancer. 

Siemens Healthineers’s Contribution in the In Vitro Diagnostics Market

Company Name  Siemens Healthineers AG
Headquarters  Erlangen, Germany, Europe 
Contribution

The company is a global provider of various healthcare products, including diagnostic products and services. In the year 2023, the company’s diagnostics segment revenue was €    36 billion.

In August 2023, Medical Physics Holdings, LLC's membership interest was fully bought by Siemens Healthineers. Cash payments of US$94 million (€85 million at the time of acquisition) were made for the transaction. Separate from the sale, Siemens Healthineers redeemed Aspekt Solutions' financial obligations, which totaled US$ 12 million (€11 million at the time of acquisition).

Recent Developments in the In Vitro Diagnostics Market

  • In August 2024, Anbio, a pioneer in the development of cutting-edge diagnostic solutions, demonstrated its most extensive portfolio of over 300 items that may be used in a variety of point-of-care testing (POCT) situations, as well as its most complete in vitro diagnostics (IVD) solutions.
  • In August 2024, a strategic agreement (the agreement) in the area of cancer molecular diagnostics was established between Hitachi High-Tech Corporation and Gencurix, Inc. Building a testing service for molecular diagnoses of cancer is the Partnership's goal.
  • In March 2024, clinical laboratories may now use the SARAPLEXTM Influenza Multiplex (IFM) Test Kit as an in vitro diagnostic (commonly known as "IVD") to identify and differentiate between influenza A and influenza B. This is because CoSara Diagnostics Pvt Ltd, the company's joint venture for manufacture and sales in India, was given approval by the Central Drugs Standard Control Organization (commonly known as "CDSCO") in India.
  • In November 2023, the Dutch city of Culemborg, A new IVD (in vitro diagnostics) product line for the healthcare sector, was introduced by Newland EMEA, a prominent player in the AIDC market. The company displayed the new devices at MEDICA, the largest medical exhibition in Dusseldorf.

In Vitro Diagnostics Market: U.S. Shipment Details and Trade Insights

CONSIGNEE NAME SHIPPER NAME PRODUCT DESCRIPTION QUANTITY WEIGHT
METROPOLITAN KITCHENS AND COUNTER TOP GOLDEN HOUSE DECORATION AND FURNITURE HOLLOW LUAN DOOR MEDICINE CABINET WHITE 1420 13500
PBC NUTRITIONALS INC CHAUCER FOODS FREEZE DRIED SMOOTHIE ORGANICNET 17794 4228
ASP GLOBAL MANUFCATURING GMBH TERRAGENE 1 40HQ RHC 15 PALLETS - FCL 1 40HQ RHC 16 PALLETS 31 11100
CHR HANSEN INC CHR HANSEN A S NUTRITIONAL SUPPLEMENTS 12 4273
ABBOTT LABORATORIES ABBOTT IRELAND C O DIAGNOSTICS DI ARCHITECT CONC WSH BFR LOW VALUE NON-HAZ PHARMA 2220 10910
ILLUMINA CAMBRIDGE LIMITED ILLUMINA SINGAPORE PRIVATE LIMITED 1X40 HR CONTAINER SAID TO CONTAIN: (DIAGNOSTIC, LABORATORY, REAGENTS) 8 1809
BECKMAN COULTER INCORPORATED BECKMAN COULTER DISTRIBUTION B V MEDICAL INSTRUMENTS 207 23006